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Abstract
Background—Perchlorate and similar anions compete with iodine for uptake into the thyroid by 
the sodium iodide symporter (NIS). This may restrict fetal growth via impaired thyroid hormone 
production.
Methods—We collected urine samples from 107 pregnant women and used linear regression to 
estimate differences in newborn size and gestational age associated with increases in perchlorate, 
thiocyanate, nitrate, and perchlorate equivalence concentrations (PEC; measure of total NIS 
inhibitor exposure).
Results—NIS inhibitor concentrations were not associated with newborn weight, length, or 
gestational age. Each 2.62 ng/µg creatinine increase in perchlorate was associated with smaller 
head circumference (0.32 cm; 95% CI: −0.66, 0.01), but each 3.38 ng/µg increase in PEC was 
associated with larger head circumference (0.48 cm; −0.01, 0.97).
Conclusions—These anions may have effects on fetal development (e.g. neurocognitive) that 
are not reflected in gross measures. Future research should focus on other abnormalities in 
neonates exposed to NIS inhibitors.
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1. Introduction
Perchlorate (ClO4−) is an inorganic ion that is commercially produced for use as an oxidant 
in explosives, pyrotechnics, and rocket fuel [1,2]. Perchlorate can also form naturally 
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through atmospheric reactions, and human exposure can occur via groundwater 
contamination and dietary intake of contaminated food crops [2]. In 2011 the United States 
Environmental Protection Agency (EPA) determined that perchlorate met the criteria for 
regulation as a drinking water contaminant, primarily based on the scientific evidence of 
perchlorate’s effects on thyroid function [3–4]. Perchlorate competes with iodide for 
transport into the thyroid via the sodium/iodide symporter (NIS), thus inhibiting iodide 
uptake into the thyroid and possibly reducing thyroid hormone production [5–6].
Thiocyanate (SCN−) and nitrate (NO3−) anions are also competitive inhibitors of thyroidal 
iodide uptake via the NIS [5], though their potencies for inhibiting iodide transport are only 
1/15 and 1/240 that of perchlorate, respectively [4]. Thiocyanate is a by product of the 
breakdown of hydrogen cyanide in cigarette smoke, and it is also produced during the 
digestion and metabolism of some plant foods [7]. Nitrates also occur naturally in many 
plants [8]. and are common components of agricultural fertilizers and sewage which can 
contaminate drinking water sources [9].
Pregnant women and their fetuses comprise a particularly vulnerable population for whom 
the inhibition of iodide uptake can have substantial consequences. Fetal growth, particularly 
fetal brain development, is largely dependent on the bioavailability of iodide for thyroid 
hormone production in both the mother and fetus [10]. The NIS is also expressed in the 
placenta, thus providing a route for iodide transport from maternal to fetal circulation. NIS 
expression in placenta, however, can also facilitate transport of perchlorate, thiocyanate, and 
nitrate into the fetal compartment [11]. leading to fetal exposure, which may threaten thyroid 
function and fetal growth. Impairments in maternal thyroid hormone production during 
pregnancy may also contribute to shortened gestation and an increased risk of preterm birth 
[12–14]. Though several studies have examined the relationship between prenatal exposure 
to NIS inhibitors and neonatal thyroid hormones, these studies have relied mainly on 
ecologically based exposure measures such as contaminant concentrations in local drinking 
water [15–21]. Few studies have examined the association between fetal growth and prenatal 
exposure to NIS inhibitors.
Previously, we reported strong positive correlations between maternal urinary 
concentrations of NIS inhibitors and concentrations in cord blood and amniotic fluid [22]. 
suggesting that maternal urinary measures of these NIS inhibitors may be effective 
surrogates for fetal exposures. Though our prior study did not show an association between 
fetal growth and NIS inhibitor concentrations in cord blood, the study population consisted 
of healthy, iodine-replete pregnant women undergoing elective cesarean sections.
To date, no study has examined the relationship between maternal urinary levels of NIS-
inhibitors and fetal growth, nor has any study examined this relationship among pregnant 
women at high-risk for alterations in fetal growth. Therefore, we conducted a prospective 
study of the association between NIS inhibitor concentrations in maternal urine samples 
throughout pregnancy and anthropometric measures at birth among a sample of women at 
risk for adverse pregnancy outcomes. We hypothesized that maternal urinary levels of 
perchlorate, thiocyanate, and nitrate during pregnancy would be negatively associated with 
neonatal weight, length, head circumference, and gestational age.
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2. Methods
2.1. Study population
The study population and protocol for this study have been described previously [23]. 
Briefly, we recruited 107 pregnant women (9–39 weeks gestation at enrollment) between 
December 2008 and July 2010 from the High-Risk Obstetric Clinic at Robert Wood Johnson 
University Hospital. Having a previous preterm delivery was the most common indication 
for a high-risk pregnancy among the sample (33%), followed by hypertension (19%) and 
diabetes (16%; Table 1). Subjects were at least 18 years old and expecting singleton infants. 
All subjects provided informed consent prior to participation in the study, which was 
approved by the Institutional Review Board at the University of Medicine and Dentistry of 
New Jersey-Robert Wood Johnson Medical School. The Centers for Disease Control and 
Prevention (CDC) involvement was limited to analyzing coded specimens and interpreting 
results.
2.2. Study protocol
All mothers initially provided a detailed medical history and information on household 
product use, occupation, hobbies, diet, and demographic variables. At each subsequent clinic 
visit, mothers provided a clean-catch urine sample. The total number of clinic visits and 
urine samples per subject ranged from 1 to 12 (mean ± standard deviation: 4 ± 3), and 84 
(79%) subjects provided multiple samples throughout their pregnancy. There was an average 
of 20 days (±16) between samples among women who completed multiple study visits.
2.3. Quantification of urinary iodide and NIS inhibitors
Perchlorate, thiocyanate, nitrate, and iodide were analyzed by isotope dilution and ion 
chromatography/tandem mass spectroscopy (IC–MS/MS) using previously published 
methods with minor modifications [24]. Briefly, 0.250 mL of urine samples were diluted to 
1.0 mL with aqueous internal standard solution containing stable isotope labeled perchlorate 
(Cl18O4−), thiocyanate (SC15N−), nitrate (15NO3−), and iodide (129I). Urinary creatinine was 
measured based on enzymatic reaction using the Roche Creatinine Plus assay (Roche 
Product Application #11775685216v19).
Samples were vortex mixed and queued for injection (25 µL). Each analytical batch 
consisted of a blank, calibration standards, and four quality control (QC) samples (two QC 
low and two QC high). Analyte quantification was based on the peak area ratio of the 
analyte to stable isotope-labeled internal standard. The assay limit of detection was 0.05 
ng/mL for perchlorate, 20 ng/mL for thiocyanate, and 700 ng/mL for nitrate. Reported 
results met the accuracy and precision guidelines of the quality assurance/quality control 
program of the Division of Laboratory Sciences, National Center for Environmental Health, 
CDC [25,26].
We also calculated a perchlorate equivalence concentration (PEC) for each urine sample by 
summing the product of the molar concentrations of each NIS inhibitor and its respective 
potency factor. The PEC calculation is based on evidence that thiocyanate and nitrate 
possess only 1/15 and 1/240, respectively, of the potency of perchlorate to inhibit iodide 
Evans et al. Page 3
Reprod Toxicol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
transport at the NIS [5]. Perchlorate, thiocyanate, nitrate, and iodide levels are reported as 
creatinine-adjusted concentrations, whereas PEC was calculated using molar concentrations.
2.4. Neonatal measurements
Gestational ages were determined based on the best obstetric estimate in the medical record, 
using either sonographic dating or date of implantation. These were all found to be 
consistent with physical examination of the infant. Birth weight, length, and head 
circumference were measured during the first hour of life, after drying but before the first 
feeding. Length and head circumference were determined by certified neonatal nurses, using 
flexible tape measures.
2.5. Statistical analyses
We calculated descriptive statistics for infant and maternal characteristics and maternal risk 
factors for adverse pregnancy outcomes, and distributions of all maternal exposure variables 
and neonatal outcome measurements. We then calculated mean pregnancy concentrations of 
urinary perchlorate, thiocyanate, nitrate, iodide, and PEC by averaging the concentrations 
across all samples for each subject. We also calculated mean concentrations of all urinary 
analytes within the second trimester only and within the third trimester only for each subject. 
Because very few women (n = 8) provided urine samples during their first trimester, we did 
not calculate mean first-trimester exposures. We then computed Pearson correlation 
coefficients between all whole-pregnancy, second-trimester, and third-trimester average 
urinary concentrations of the NIS inhibitors and iodide, weighted by the number of urine 
samples per mother.
For our main analyses, we used weighted multivariable linear regression to estimate the 
changes in infant weight (g), length (cm), head circumference (cm), and gestational age 
(weeks) associated with interquartile range (IQR) increases in mean pregnancy 
concentrations of each analyte. All regression models were weighted by the number of urine 
samples per subject. We ran separate regression models using each analyte as the primary 
exposure for each of the four outcomes. All weight, length, and head circumference models 
included maternal smoking (sometimes/often [once per month to daily] vs. never/rarely 
[never to 1–2 times only]), nulliparity, infant gender, and gestational age, as these covariates 
were found to be associated with one or more of the maternal exposure variables and one or 
more of the outcome variables. All gestational age models included maternal race/ethnicity 
and paternal employment status (employed vs. unemployed). These models were run among 
all 107 subjects, and among only those subjects with term births (≥37 completed weeks of 
gestation; n = 81).
We also conducted sensitivity analyses to examine whether mean maternal urinary NIS 
inhibitor concentrations in either the second or third trimester were associated with infant 
measurements. Again, we used weighted multivariable linear regression to estimate the 
changes in infant measurements associated with IQR increases in mean second- and third-
trimester maternal concentrations of each analyte, including the same covariates as 
described above. We also ran these regression models using analyte concentrations from the 
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last urine sample before delivery as the exposure of interest. All statistical analyses were 
conducted using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
3. Results
Subject characteristics and maternal risk factors for adverse pregnancy outcomes are shown 
in Table 1. There was a nearly equal distribution of white, black, and Hispanic mothers, and 
more than half had some college education. Most mothers reported never smoking during 
their pregnancy, and most had at least one previous pregnancy. Previous preterm delivery 
was the most common indication for referral to the high-risk clinic. None of the mothers 
reported having a thyroid disease of any kind.
Table 2 shows the distributions of the number of urine samples per subject, mean urinary 
perchlorate, thiocyanate, nitrate, iodide, and PEC concentrations in the whole pregnancy, 
second trimester, third trimester, and last sample before birth, and infant outcome 
measurements. All four analytes were detected in 100% of the urine samples for all subjects. 
There were moderate-to-strong positive correlations of whole-pregnancy, second-trimester, 
third-trimester, and last-sample perchlorate concentrations with nitrate and iodide (rs = 
0.30–0.64, p < 0.05; Table 3). Nitrate was also moderately correlated with urinary iodide 
and thiocyanate over three of the four time periods analyzed (rs = 0.30–0.33, p < 0.05). The 
composite measure of NIS inhibitor concentrations, PEC, was significantly correlated with 
thiocyanate and nitrate concentrations(rs = 0.19–0.35, p < 0.05), but not with urinary 
perchlorate or iodide. The results of the main regression analyses estimating changes in 
infant measurements and gestational age per IQR increases in mean whole pregnancy 
analyte concentrations are shown in Table 4. Interquartile range increases in perchlorate, 
thiocyanate, nitrate, and PEC concentrations were not associated with decreases in infant 
weight, length, or gestational age among all subjects or among term births (37–41 weeks). 
Each 2.62 ng/µg creatinine increase in mean whole-pregnancy perchlorate concentration was 
associated with a 0.32 cm decrease (95% CI: −0.66, 0.01) in infant head circumference 
among all subjects, and a 0.38 cm decrease (95% CI: −0.74, −0.03) among term births. Each 
3.38 ng/µg increase in PEC was associated with a 0.48 cm increase (95% CI: −0.01, 0.97) in 
head circumference among all infants, and a 0.38 cm increase (95% CI: −0.20, 0.96) among 
term births (Table 4).
Table 5 shows the results of sensitivity analyses estimating changes in infant outcomes per 
IQR increases in maternal exposures in the second and third trimesters and in the last urine 
sample before delivery among all subjects. Only 40 mothers provided urine samples in the 
second trimester, whereas nearly all (n = 104; 97) provided at least one sample in the third 
trimester. The changes in infant weight, length, head circumference, and gestational age 
associated with increases in analyte concentrations were generally slightly smaller or 
unchanged compared to the changes associated with mean whole-pregnancy concentrations 
(Table 5). However, each 3.00 ng/µg increase in third trimester mean PEC concentration 
was associated with a 0.53 cm increase (95% CI: 0.06, 1.00) in head circumference. 
Additionally, each 3.29 ng/µg increase in last sample PEC concentration was associated with 
a 0.36 cm increase (95% CI: −0.04, 0.75) in infant head circumference, and each 28,459 
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ng/µg increase in last sample nitrate concentration was associated with a 0.33 cm increase 
(95% CI: −0.002, 0.66) in head circumference (Table 5).
4. Discussion
In this prospective study of fetal growth and maternal urinary concentrations of inhibitors of 
thyroidal iodine uptake, increased maternal urinary concentrations of perchlorate, 
thiocyanate, and nitrate were generally not associated with differences in newborn weight, 
length, or gestational age. Though we did observe increased mean maternal concentrations 
of perchlorate during pregnancy to be associated, as hypothesized, with smaller infant head 
circumference, most of our analyses did not show a negative association between NIS 
inhibitors and neonatal size. Also, contrary to our hypothesis, we found increases in third 
trimester and mean pregnancy PEC, a composite measure of NIS inhibitor exposure, to be 
associated with increases in neonatal head circumference.
To our knowledge, no previous study has examined the relationship between newborn 
growth measurements and these anion concentrations in maternal urine. Among the few 
studies that have looked at differences in fetal growth in relation to maternal NIS inhibitor 
exposure, maternal exposure classification has been primarily based on the concentrations of 
NIS inhibitors in drinking water, with no direct assessment of biological toxicant 
concentrations [16,18,22]. Bukwoski et al. observed up to a 156% (95% CI: 44–445%) 
greater odds of intrauterine growth restriction (<2500 g at birth) among infants born to 
mothers whose residence at the time of delivery was in a community with higher 
concentrations of nitrate in the drinking water, compared to areas with the lowest nitrate 
levels [18]. Tellez et al. [22] and Amitai et al. [16] observed no differences in weight, 
length, head circumference, or gestational age among the newborns of women residing in 
cities with mean drinking water perchlorate levels ranging from 0.5 ng/mL to 340 ng/mL. 
However, the use of ecological data as proxies for individual exposure levels may have 
introduced some degree of bias due to exposure misclassification. The likelihood of 
misclassification, though, would not be expected to vary based on neonatal outcomes, and so 
the results of those studies may be underestimates of the effect of NIS inhibitors on fetal 
growth.
The negative relationship between maternal perchlorate and infant head circumference is 
consistent with a causal model in which perchlorate inhibits iodide uptake in the maternal 
and/or fetal thyroid, thereby reducing thyroid hormone production and impairing fetal 
growth. Fetal serum thyroid hormone (T4) concentration rises gradually until about 36 
weeks of gestation [27]. and fetal T4 production is responsible for an increasing amount of 
the biologic activity of thyroid hormone in the fetus from mid-gestation onward [10]. The 
placenta is largely permeable to perchlorate, with fetal doses calculated at up to 82% of 
maternal dose in late gestation. Animal studies suggest that the fetal thyroid is more 
sensitive to the suppressive effects of perchlorate than the adult thyroid [28]. At the same 
time, the placenta remains weakly permeable to the passage of maternal T4 even in the third 
trimester. Therefore, impaired fetal or maternal thyroid function secondary to perchlorate 
exposure could contribute to relative hypothyroidism in the fetus, which is associated with 
impaired growth, maturation, and brain development [29,30]. Animal models have shown an 
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association between maternal hypothyroidism and decreased brain size [31]. and Blazer et 
al. [32] have reported decreased head circumference in the children of hypothyroid mothers 
despite therapeutic supplementation. In contrast, large head size has been noted in several 
reports on infants with congenital hypothyroidism [33–35]. The interaction of perchlorate, 
thyroid hormone levels, and growth of the brain and calvarium is likely a complex 
phenomenon that is dependent on timing, duration, and variability of exposure, as well as 
interaction with other NIS inhibitors such as nitrate.
We previously examined the relationship between cord blood concentrations of NIS 
inhibitors and newborn size among a sample of healthy mothers with full-term pregnancies 
[23]. In that study, we did not observe trends of decreasing newborn weight, length, or head 
circumference across increasing quartiles of cord blood perchlorate, thiocyanate, nitrate, or 
PEC. For example, compared to the lowest quartile of cord blood perchlorate (≤0.095 µg/L), 
the upper quartiles (0.095–0.139 µg/L; 0.139–0.223 µg/L; ≥0.223 µg/L) were not associated 
with significant decreases in infant birth weight (2nd quartile: −99 g (95% CI: −332, 135); 
3rd quartile: −100 g (−306, 106); 4th quartile: 19 g (−189, 227); p for trend 0.98). There 
was, however, a pattern of increasing head circumference across increasing quartiles of cord 
blood nitrate concentrations. Compared to the lowest quartile of cord blood nitrate (≤1900 
µg/L), the second (1900–2480 µg/L), third (2480–3310 µg/L), and fourth (3310–4530 µg/L) 
quartiles were associated with 0.06 cm (95% CI: −0.65, 0.78), 0.12 cm (−0.60, 0.84), and 
0.76 cm (0.03, 1.48) increases, respectively, in neonatal head circumference (p for trend = 
0.06). This is similar to the results of the current analysis of maternal urinary PEC and infant 
head circumference. Here, we observed a 0.48 cm increase (95% CI: −0.01, 0.97) in head 
circumference per 3.36 ng/µg increase in maternal urinary PEC, the combined measure of 
NIS inhibitor concentrations. However, our previous study did not show a trend of 
increasing head circumference across increasing quartiles of cord blood PEC (2nd quartile: 
0.78 cm (95% CI: 0.05, 1.52); 3rd quartile: 0.25 cm (−0.46, 0.96); 4th quartile: 0.32 cm 
(−0.39, 1.03); p for trend = 0.72). Though the results of the current PEC analysis appear to 
contradict the negative relationship between perchlorate and head circumference, it should 
be noted that maternal urinary PEC concentrations were more strongly correlated with 
maternal thiocyanate and nitrate than with perchlorate concentrations in this sample. Though 
thiocyanate is a known metabolite of cigarette smoke, it is also produced during the 
digestion of various plant foods. Given that nitrate is also consumed via plant foods, it may 
be possible that higher PEC concentrations in this sample are associated with greater fruit 
and vegetable consumption. This could potentially explain the positive relationship observed 
between PEC and head circumference, since maternal diets higher in fruits and vegetables 
have been associated with greater infant birth measurements, including head circumference 
[36–40]. However, this study did not collect sufficient dietary data to assess this 
relationship. It should also be noted that although the current methods were partly based on 
previous work showing an association between anion concentrations in maternal urine and 
the fetal compartment, that relationship was established among healthy mothers. It is unclear 
whether a similar relationship is present among high-risk pregnancies such as those 
examined here.
The lack of associations between NIS inhibitors and most birth outcomes measured in this 
study could be attributable to sufficient levels of maternal iodine intake in this sample. 
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Iodine deficiency is generally diagnosed across whole populations as a median urinary 
iodide concentration <100 ng/mL, though this cut-off level is often used to categorize 
individuals in studies of NIS inhibitor effects. Blount et al. analysis of data from the 
National Health and Nutrition Examination Survey (NHANES) showed a negative 
relationship between urinary perchlorate concentrations and serum thyroxine (T4) only 
among adolescent and adult females with urinary iodine concentrations <100 ng/mL [41]. 
The distribution of mean pregnancy urinary iodide concentrations in this sample (median = 
156 ng/µg creatinine; range 45–1097 ng/µg) indicates that only about one quarter of the 
mothers in this study fell below the 100 ng/mL threshold. Therefore, sufficient thyroid 
hormone production in these mothers and their fetuses may have been maintained via 
adequate iodine nutrition. We did observe a greater negative effect on neonatal length of 
mean pregnancy thiocyanate concentrations among mothers with <100 ng/µg mean urinary 
iodide (1.72 cm [95% CI: −3.95, 0.50] decrease per IQR increase vs. 0.17 decrease [−0.77, 
0.43] among mothers >100 ng/µg iodide; interaction p = 0.03). We also observed a greater 
negative effect on gestational age of mean pregnancy PEC among mothers with higher 
iodide concentrations (≥100 ng/µg:1.02 wk [−1.96, −0.08] decrease per IQR increase vs. 
<100 ng/µg: 0.18 wk [−1.07, 0.70] decrease; interaction p = 0.04). However, given the large 
number of statistical tests conducted, it is possible that those interactions and our other 
significant findings may be due to chance alone. Additionally, since there are currently no 
established reference ranges for urinary concentrations of these NIS inhibitors, it is unclear 
whether our current and previous results are due to maternal concentrations being below a 
biologically relevant threshold.
Although this study had several strengths, including biological measures of maternal NIS 
inhibitor exposures, urine samples collected at multiple time points during pregnancy, and 
urinalysis conducted at the CDC perchlorate laboratory, there are several limitations that 
should be considered when making inference. First, the power to detect a meaningful change 
in infant growth measures associated with maternal NIS concentrations may have been 
limited by the relatively small sample size of this study. However, our results suggest no 
clear pattern of response across any maternal exposures or infant outcomes, and so it is 
unlikely that our sample size prevented us from observing significant associations.
Second, this study was a secondary analysis of urine samples obtained for a separate study 
of prenatal phthalate exposure and gestational age [24], and so there was no a priori 
protocol in place to ensure uniformity in the timing or number of samples collected across 
subjects. Although most subjects (79%) provided multiple samples throughout their 
pregnancy, the majority of samples (78%) were obtained in the third trimester and there was 
wide variability in the number of samples per subject (range: 1–12). Given that the fetus is 
entirely dependent on circulating maternal thyroid hormones during the first 13–15 weeks of 
gestation [11], the inhibition of maternal thyroid hormone production by NIS inhibitors in 
the first trimester may be particularly detrimental to fetal growth. However, only eight 
subjects (7%) in this study provided at least one urine sample during their first trimester, and 
so we were unable to assess the association between first trimester NIS inhibitor exposures 
and neonatal outcomes. The lack of maternal NIS inhibitor concentrations during what may 
be the most relevant period of exposure may have biased our effect estimates toward the null 
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and could explain the lack of any pattern of response across exposures or outcomes. Future 
studies should collect more urine samples during the first trimester in order to examine the 
association between earlier prenatal NIS inhibitor exposures and fetal growth. Future studies 
should also concurrently measure maternal and/or neonatal T4 or TSH levels to determine 
whether observed associations between NIS inhibitors and neonatal size are mediated by 
changes in thyroid function. Further, there may have been error in whole pregnancy 
maternal exposure measurements given that the majority of subjects (n = 66; 61.7%) only 
provided urine samples during their third trimester. However, there were no differences in 
infant outcomes between mothers who provided samples during multiple trimesters versus 
those whose samples were from their third trimester only. This non-differential exposure 
misclassification may have biased our effect estimates toward no association between 
maternal exposures and infant outcomes.
Finally, there may also be some degree of outcome misclassification in this study, given that 
we used weight, length, and head circumference at birth as surrogate measures of fetal 
growth. We did not measure fetal size in utero at the time of each urine sample, and so we 
could not assess whether maternal urinary NIS inhibitor concentrations were associated with 
the trajectory of fetal growth throughout gestation.
5. Conclusions
We did not observe the hypothesized pattern of decreased neonatal size associated with 
exposure to increased prenatal concentrations of inhibitors of thyroidal iodide uptake. These 
anions may have more subtle effects on fetal development (e.g. neurocognitive effects) that 
are not reflected in such gross measures as those examined in this study. Future research of 
prenatal NIS inhibitor exposure should focus on other developmental abnormalities in 
infants and utilize multiple maternal samples during the most critical prenatal developmental 
periods.
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Table 1
Characteristics of study subjects.
N (%)
Infant gender
  Male 59 (55)
  Female 48 (45)
Preterm birth (≤36 weeks; study pregnancy) 26 (25)
Maternal age
  20–24 20 (19)
  25–29 28 (26)
  30–34 17 (16)
  35–39 29 (27)
  ≥40 13 (12)
Maternal race/ethnicity
  White 33 (31)
  Black 27 (25)
  Hispanic 35 (33)
  Other 11 (10)
  Missing 1 (1)
Maternal education
  <High school graduate 20 (19)
  High school graduate 26 (24)
  Some college 27 (25)
  College degree 33 (31)
  Missing 1 (1)
Maternal employment status
  Employed 50 (47)
  Unemployed 51 (48)
  Missing 6 (6)
  Smoked during pregnancy
  Never 86 (82)
   Rarely 3 (3)
  Sometimes 5 (5)
  Often 11 (10)
Number of previous pregnancies
  0 17 (16)
  1 29 (27)
  2 21 (20)
  3 21 (20)
  ≥4 19 (18)
Indication for high-risk pregnancy
  Congenital anomaly 4 (4)
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N (%)
  Previous preterm delivery 35 (33)
  Diabetes 17 (16)
  Hypertension 21 (19)
  Urinary infection 8 (7)
  Febrile illness 14 (13)
  Missing 8 (7)
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Table 3
Spearman correlations between whole pregnancy (n = 107), 2nd trimester (n = 40), 3rd trimester (n = 104), 
and last sample (n = 107) concentrations of NIS inhibitors and iodide in maternal urine.
Thiocyanate Nitrate PEC Iodide
Perchlorate
Whole pregnancya 0.11 0.47b −0.05 0.58b
2nd trimester 0.12 0.64b 0.05 0.30
3rd trimester 0.09 0.46b −0.08 0.61b
Last sample 0.14 0.40b −0.11 0.57b
Thiocyanate
Whole pregnancy – 0.28b 0.27b 0.02
2nd trimester – 0.04 0.35b −0.01
3rd trimester – 0.30b 0.26b 0.04
Last sample – 0.32b 0.18 0.12
Nitrate
Whole pregnancy – – 0.20b 0.30b
2nd trimester – – 0.23 0.12
3rd trimester – – 0.19b 0.33b
Last sample – – 0.27b 0.31b
PEC
Whole pregnancy – – – −0.16
2nd trimester – – – −0.29
3rd trimester – – – −0.19
Last sample – – – −0.17
aWhole pregnancy, 2nd trimester, and 3rd trimester correlations;
b
p < 0.05.
Reprod Toxicol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Evans et al. Page 17
Ta
bl
e 
4
Ch
an
ge
s i
n 
in
fa
nt
 w
ei
gh
t, 
le
ng
th
, h
ea
d 
ci
rc
um
fe
re
nc
e,
 a
nd
 g
es
ta
tio
na
l a
ge
 a
ss
oc
ia
te
d 
w
ith
 in
te
rq
ua
rti
le
 ra
ng
e 
(IQ
R)
 in
cre
ase
s i
n m
ea
n w
ho
le 
pre
gn
an
cy
 
ex
po
su
re
s.
A
ll 
su
bje
cts
Te
rm
 b
ir
th
s
IQ
R 
(n
g/µ
g)
N
β (
95
%
 C
I)
p
N
β (
95
%
 C
I)
p
W
ei
gh
t, 
gr
am
sa
Pe
rc
hl
or
at
eb
2.
62
10
7
−
63
.7
 (−
17
1.5
, 4
4.1
)
0.
24
81
−
68
.0
 (−
18
9.2
, 5
3.2
)
0.
27
Th
io
cy
an
at
e
10
26
10
7
−
27
.3
 (−
92
.4,
 37
.8)
0.
41
81
−
23
.5
 (−
93
.2,
 46
.3)
0.
51
N
itr
at
e
25
,0
59
10
7
6.
6 
(−
12
2.1
, 1
35
.3)
0.
92
81
85
.3
 (−
10
6.1
, 2
76
.7)
0.
38
PE
Cc
3.
38
10
7
20
.5
 (−
13
9.9
, 1
80
.9)
0.
80
81
9.
5 
(−
18
6.6
, 2
05
.7)
0.
92
Io
di
de
14
1
10
7
32
.9
 (−
58
.5,
 12
4.2
)
0.
48
81
30
.5
 (−
68
.0,
 12
9.1
)
0.
54
Le
ng
th
, c
m
Pe
rc
hl
or
at
e
2.
62
10
7
−
0.
06
 (−
0.9
1, 
0.7
9)
0.
89
81
0.
03
 (−
0.9
6, 
1.0
1)
0.
96
Th
io
cy
an
at
e
10
26
10
7
−
0.
17
 (−
0.6
8, 
0.3
4)
0.
51
81
−
0.
05
 (−
0.6
1, 
0.5
1)
0.
85
N
itr
at
e
25
,0
59
10
7
−
0.
12
 (−
1.1
3, 
0.8
9)
0.
82
81
0.
14
 (−
1.4
0, 
1.6
9)
0.
86
PE
C
3.
38
10
7
0.
09
 (−
1.1
7, 
1.3
6)
0.
88
81
0.
07
 (−
1.5
0, 
1.6
5)
0.
93
Io
di
de
14
1
10
7
0.
15
 (−
0.5
7, 
0.8
7)
0.
68
81
0.
15
 (−
0.6
4, 
0.9
5)
0.
70
H
ea
d 
ci
rc
., 
cm
Pe
rc
hl
or
at
e
2.
62
10
5
−
0.
32
 (−
0.6
6, 
0.0
1)
0.
06
80
−
0.
38
 (−
0.7
4, 
−0
.03
)
0.
03
Th
io
cy
an
at
e
10
26
10
5
0.
05
 (−
0.1
5, 
0.2
6)
0.
60
80
0.
08
 (−
0.1
3, 
0.2
9)
0.
46
N
itr
at
e
25
,0
59
10
5
0.
07
 (−
0.3
3, 
0.4
7)
0.
73
80
0.
02
 (−
0.5
6, 
0.6
1)
0.
92
PE
C
3.
38
10
5
0.
48
 (−
0.0
1, 
0.9
7)
0.
06
80
0.
38
 (−
0.2
0, 
0.9
6)
0.
19
Io
di
de
14
1
10
5
0.
03
 (−
0.2
6, 
0.3
1)
0.
86
80
−
0.
00
 (−
0.3
0, 
0.2
9)
0.
98
G
es
ta
tio
na
l a
ge
, w
ee
ks
d
Pe
rc
hl
or
at
e
2.
62
10
4
0.
34
 (−
0.1
2, 
0.7
9)
0.
15
80
0.
12
 (−
0.1
2, 
0.3
6)
0.
32
Th
io
cy
an
at
e
10
26
10
4
0.
02
 (−
0.2
1, 
0.2
5)
0.
87
80
−
0.
02
 (−
0.1
3, 
0.1
0)
0.
76
N
itr
at
e
25
,0
59
10
4
−
0.
16
 (−
0.7
3, 
0.4
2)
0.
59
80
0.
07
 (−
0.3
3, 
0.4
7)
0.
73
PE
C
3.
38
10
4
−
0.
46
 (−
1.1
0, 
0.1
8)
0.
15
80
−
0.
19
 (−
0.5
5, 
0.1
7)
0.
30
Io
di
de
14
1
10
4
0.
08
 (−
0.3
0, 
0.4
7)
0.
67
80
0.
00
 (−
0.2
0, 
0.1
9)
0.
97
a
W
ei
gh
t, 
le
ng
th
, a
nd
 h
ea
d 
ci
rc
um
fe
re
nc
e 
m
od
el
s i
nc
lu
de
 m
at
er
na
l s
m
ok
in
g,
 n
ul
lip
ar
ity
, i
nf
an
t g
en
de
r, 
an
d 
ge
sta
tio
na
l a
ge
.
Reprod Toxicol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Evans et al. Page 18
b P
er
ch
lo
ra
te
, t
hi
oc
ya
na
te
, n
itr
at
e,
 a
nd
 io
di
de
 c
on
ce
nt
ra
tio
ns
 a
re
 c
re
at
in
in
e-
ad
jus
ted
 (n
g/µ
g c
rea
tin
ine
).
c P
EC
: p
er
ch
lo
ra
te
 e
qu
iv
al
en
ce
 c
on
ce
nt
ra
tio
n 
(m
ola
r c
on
ce
ntr
ati
on
s)=
(pe
rch
lor
ate
)+
(ni
tra
te/
24
0)+
(th
ioc
ya
na
te/
15
).
d G
es
ta
tio
na
l a
ge
 m
od
el
s i
nc
lu
de
 m
at
er
na
l r
ac
e/
et
hn
ic
ity
 a
nd
 p
at
er
na
l e
m
pl
oy
m
en
t s
ta
tu
s; 
al
l m
od
el
s w
ei
gh
te
d 
by
 n
um
be
r o
f u
rin
e 
sa
m
pl
es
 p
er
 su
bje
ct.
Reprod Toxicol. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Evans et al. Page 19
Ta
bl
e 
5
Ch
an
ge
s i
n 
ne
on
at
al
 m
ea
su
re
m
en
ts 
an
d 
ge
sta
tio
na
l a
ge
 p
er
 in
te
rq
ua
rti
le
 ra
ng
e 
in
cr
ea
se
s i
n 
ex
po
su
re
s i
n 
th
e 
2n
d 
an
d 
3r
d 
tri
m
es
te
r a
nd
 th
e 
la
st 
sa
m
pl
e 
be
fo
re
 d
el
iv
er
y.
W
ei
gh
t (
gr
am
s)a
Le
ng
th
 (c
m)
H
ea
d 
ci
rc
um
fe
re
nc
e 
(cm
)
G
es
ta
tio
na
l a
ge
 (w
ee
ks
)b
IQ
R 
(n
g/µ
g)
N
β (
95
%
 C
I)
p
N
β (
95
%
 C
I)
p
N
β (
95
%
 C
I)
p
N
β (
95
%
 C
I)
p
2n
d 
tri
m
es
te
rc
Pe
rc
hl
or
at
ed
1.
94
40
−
0.
6 
(−
44
.9,
 43
.7)
0.
98
40
−
0.
07
 (−
0.3
8, 
0.2
5)
0.
67
39
−
0.
03
 (−
0.1
5, 
0.0
9)
0.
60
40
0.
03
 (−
0.2
6, 
0.3
2)
0.
81
Th
io
cy
an
at
e
63
8
40
11
1.
5 
(−
11
0.4
, 3
33
.3)
0.
31
40
1.
10
 (0
.45
, 2
.65
)
0.
16
39
0.
15
 (−
0.4
6, 
0.7
7)
0.
62
40
0.
05
 (−
0.5
7, 
0.6
8)
0.
86
N
itr
at
e
19
,5
36
40
−
27
.4
 (−
12
3.7
, 6
9.0
)
0.
57
40
−
0.
15
 (−
0.8
4, 
0.5
3)
0.
65
39
−
0.
02
 (−
0.2
9, 
0.2
4)
0.
86
40
0.
10
 (−
0.5
9, 
0.7
8)
0.
77
PE
Ce
4.
16
40
−
37
.4
 (−
25
6.9
, 1
82
.2)
0.
73
40
0.
06
 (−
1.4
9, 
1.6
2)
0.
93
39
−
0.
00
02
 (−
0.6
1, 
0.6
1)
0.
99
40
−
0.
26
 (−
1.5
9, 
1.0
8)
0.
70
Io
di
de
13
4
40
18
.6
 (−
15
0.2
, 1
87
.3)
0.
82
40
−
0.
14
 (−
1.3
3, 
1.0
5)
0.
81
39
0.
28
 (−
0.1
8, 
0.7
4)
0.
22
40
−
0.
24
 (−
1.3
0, 
0.8
3)
0.
66
3r
d 
tri
m
es
te
r
Pe
rc
hl
or
at
e
2.
93
10
4
−
49
.2
 (−
15
0.4
, 5
2.1
)
0.
34
10
4
0.
02
 (−
0.7
8, 
0.8
3)
0.
96
10
2
−
0.
19
 (−
0.5
0, 
0.1
3)
0.
25
10
1
0.
20
 (−
0.1
5, 
0.5
5)
0.
27
Th
io
cy
an
at
e
11
27
10
4
−
33
.6
 (−
99
.0,
 31
.9)
0.
31
10
4
−
0.
21
 (−
0.7
3, 
0.3
1)
0.
43
10
2
0.
05
 (−
0.1
6, 
0.2
6)
0.
62
10
1
0.
01
 (−
0.1
8, 
0.2
0)
0.
92
N
itr
at
e
23
,0
95
10
4
37
.6
 (−
90
.1,
 16
5.1
)
0.
56
10
4
−
0.
11
 (−
1.1
3, 
0.9
0)
0.
82
10
2
0.
14
 (−
0.2
7, 
0.5
4)
0.
50
10
1
−
0.
25
 (−
0.6
9, 
0.2
0)
0.
28
PE
C
3.
00
10
4
60
.8
 (−
90
.7,
 21
2.2
)
0.
43
10
4
0.
31
 (−
0.8
9, 
1.5
2)
0.
61
10
2
0.
53
 (0
.06
, 1
.00
)
0.
03
10
1
−
0.
28
 (−
0.7
8, 
0.2
2)
0.
27
Io
di
de
15
1
10
4
43
.6
 (−
41
.7,
 12
8.9
)
0.
31
10
4
0.
26
 (−
0.4
2, 
0.9
4)
0.
44
10
2
0.
06
 (−
0.2
1, 
0.3
3)
0.
66
10
1
0.
08
 (−
0.2
1, 
0.3
6)
0.
60
La
st
 sa
m
pl
e
Pe
rc
hl
or
at
e
2.
87
10
7
−
1.
1 
(−
51
.3,
 49
.2)
0.
97
10
7
0.
07
 (−
0.3
6, 
0.5
1)
0.
74
10
5
−
0.
01
 (−
0.1
7, 
0.1
6)
0.
91
10
4
0.
04
 (−
0.2
1, 
0.2
8)
0.
76
Th
io
cy
an
at
e
11
85
10
7
−
41
.3
 (−
10
5.6
, 2
3.0
)
0.
21
10
7
−
0.
37
 (−
0.9
3, 
0.1
9)
0.
19
10
5
−
0.
07
 (−
0.2
8, 
0.1
4)
0.
52
10
4
0.
03
 (−
0.2
3, 
0.2
9)
0.
81
N
itr
at
e
28
,4
59
10
7
68
.9
 (−
29
.3,
 16
7.3
)
0.
17
10
7
0.
38
 (−
0.4
8, 
1.2
4)
0.
38
10
5
0.
33
 (−
0.0
02
, 0
.66
)
0.
05
10
4
−
0.
17
 (−
0.6
4, 
0.3
0)
0.
48
PE
C
3.
29
10
7
75
.1
 (−
45
.4,
 19
5.5
)
0.
22
10
7
0.
13
 (−
0.9
3, 
1.1
8)
0.
81
10
5
0.
36
 (−
0.0
4, 
0.7
5)
0.
08
10
4
−
0.
00
2 
(−
0.9
3, 
0.2
0)
0.
20
Io
di
de
16
0
10
7
14
.4
 (−
5.5
, 3
4.2
)
0.
15
10
7
0.
12
 (−
0.0
6, 
0.2
9)
0.
19
10
5
0.
04
 (−
0.0
3, 
0.1
0)
0.
25
10
4
−
0.
01
 (−
0.1
0, 
0.0
9)
0.
88
a
W
ei
gh
t, 
le
ng
th
, a
nd
 h
ea
d 
ci
rc
um
fe
re
nc
e 
m
od
el
s a
dju
ste
d f
or 
ma
ter
na
l s
mo
kin
g, 
nu
llip
ari
ty,
 in
fan
t g
en
de
r, a
nd
 ge
sta
tio
na
l a
ge
.
b G
es
ta
tio
na
l a
ge
 m
od
el
s a
dju
ste
d f
or 
ma
ter
na
l ra
ce/
eth
nic
ity
 an
d p
ate
rna
l e
mp
loy
me
nt 
sta
tus
.
c 2
nd
 a
nd
 3
rd
 tr
im
es
te
r m
od
el
s w
ei
gh
te
d 
by
 n
um
be
r o
f u
rin
e 
sa
m
pl
es
 p
er
 su
bje
ct.
d P
er
ch
lo
ra
te
, t
hi
oc
ya
na
te
, n
itr
at
e,
 a
nd
 io
di
de
 c
on
ce
nt
ra
tio
ns
 a
re
 c
re
at
in
in
e-
ad
jus
ted
 (n
g/µ
g c
rea
tin
ine
).
e P
EC
: p
er
ch
lo
ra
te
 e
qu
iv
al
en
t c
on
ce
nt
ra
tio
n 
(m
ola
r c
on
ce
ntr
ati
on
s) 
= (
pe
rch
lor
ate
) +
 (n
itr
ate
/24
0) 
+ (
thi
oc
ya
na
te/
15
).
Reprod Toxicol. Author manuscript; available in PMC 2016 November 01.
